MOONLAKE IMMUNOTHERAPEUTICS
MLTXNASDAQTrading Snapshot
- Day Range
- $11.38 – $11.50
- 52-Week Range
- $6.08 – $23.29
- Volume
- $1.57B
- Avg Volume
- $1.78B
- Shares Outstanding
- 84.1M
- Next Earnings
- Oct 31, 2026
Fundamentals Snapshot
- Annual Revenue
- $158M
- Last Q Revenue
- $37M
- P/E Ratio
- -3.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-3.57
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2.2%
Why Investors Own MLTX
- ✓High-growth profile — revenue up +24.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 41% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MOONLAKE IMMUNOTHERAPEUTICS
MLTX
StockOtter · stockotter.spaceAbout MOONLAKE IMMUNOTHERAPEUTICS
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy
MoonLake Immunotherapeutics offers a compelling investment case despite sonelokimab's mixed clinical results, focusing on regulatory progress and commercial viability. MLTX can file for HS approval without another major
MoonLake Immunotherapeutics Target of Unusually High Options Trading (NASDAQ:MLTX)
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) was the recipient of some unusual options trading activity on Monday. Stock traders acquired 2,707 call options on the company. This is an increase of 142% com
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
MoonLake Immunotherapeutics said on Monday its experimental drug met all main goals in a late-stage trial involving adults with an inflammatory disease who had not previously received biologic medicines.
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimab The primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab's 60 mg with induction, and signi
Arrowstreet Capital Limited Partnership Acquires New Shares in MoonLake Immunotherapeutics $MLTX
Arrowstreet Capital Limited Partnership bought a new stake in MoonLake Immunotherapeutics (NASDAQ: MLTX) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commi
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
The consensus price target hints at a 73.4% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions co